Lytix Biopharma is a clinical-stage biotech company with a highly novel technology platform using host-defense peptide-derived molecules to kill cancer cells and kick start the immune system.
With the potential to overcome major challenges in cancer treatment, we aim to improve the outcomes for cancer patients.
The majority of cancer patients do not respond to immunotherapy, due to differences between cancer cells in a tumor (heterogeneity) and lack of a broad and tumor-specific immune response.
Lytix Biopharma’s molecules overcome this challenge by killing the cancer cells, including resistant cells, and expose their internal components to the immune system. This results in an uptake of tumor antigens and the activation of tumor antigen presenting cells, thereby creating a strong, broad and long-lasting systemic T-cell response overcoming tumor heterogeneity.
Lytix Biopharma’s molecules can work in many different cancer indications and treatment settings, both as mono- and combination therapy.